董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Marc Balkin Director 50 未披露 未持股 2025-10-06
Christopher Bull Director 56 未披露 未持股 2025-10-06
Jody Aufrichtig Chairman of the Board and Strategic Business Development Officer 51 21.67万 未持股 2025-10-06
Seth Feuerstein Director 52 未披露 未持股 2025-10-06

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Neil Maresky Chief Executive Officer 61 39.00万 未持股 2025-10-06
Warwick Corden Lloyd Chief Financial Officer 45 19.50万 未持股 2025-10-06
Jody Aufrichtig Chairman of the Board and Strategic Business Development Officer 51 21.67万 未持股 2025-10-06

董事简历

中英对照 |  中文 |  英文
Marc Balkin

Marc Balkin自2021年3月起担任我们的董事兼首席执行官。Balkin先生是Balkin and Co的创始人,这是一家咨询公司,自2015年以来一直为私人股本公司和家族理财室提供合并,收购和投资非洲的建议。惠普的客户包括SAP创始人兼现任董事长Hasso Plattner博士的家族办公室、Omidyar Network(eBay创始人Pierre Omidyar家族办公室的一部分)和兰德商业银行。在创立Balkin and Co之前,Balkin先生是Hasso PlattnerVentures Africa的管理合伙人,这是一家风险基金,其中Plattner博士是关键的有限合伙人。Balkin先生还负责管理Plattner博士家族办公室的私人股本和风险资本资产的新兴市场投资组合。Balkin先生目前是Digame的合伙人,这是一家专注于非洲和中东的成长型基金,其主要投资者是阿布扎比投资顾问公司(“;ADIC”;)。Balkin先生在Direct-to-Consumer Asset Manager10X Investments的董事会中代表Digame,自2004年以来,Balkin先生在一系列风险资本和私募股权基金投资委员会任职并担任主席,作为有限合伙人或投资者的代表。这些公司包括Enablis、第一国民银行Vumela基金、Telkom Future Makers和Alithea IDF。从2000年到2007年,Balkin先生是O2Capital的创始合伙人,这是一家Msele Nedventures Fund的私募股权基金经理。该基金的有限合伙人包括一系列发展融资机构,如Proparco(法国)、DEG(德国)和IDC(南非),该基金主要投资于南非的技术企业。Balkin先生于1995年获得学士学位,并于1997年在约翰内斯堡的威特沃特斯兰德大学获得法学学士学位。


Marc Balkin has served as a director of the Company since January 25, 2024. He served as the Chief Executive Officer and served as a member of the board of directors of NCAC from March 2021 until January 25, 2024. Mr. Balkin is a founder of Balkin and Co, an advisory firm that has advised private equity firms and family offices on mergers, acquisitions and investments in Africa since 2015. Clients have included HP Bet (part of the family office of Dr. Hasso Plattner, a founder and current Chairman of SAP), Omidyar Network (part of the family office of Pierre Omidyar, the founder of eBay) and Rand Merchant Bank. Prior to founding Balkin and Co, Mr. Balkin was the Managing Partner of Hasso Plattner Ventures Africa, a Venture Fund in which Dr. Plattner was the key limited partner. Mr. Balkin also held responsibility for managing the Emerging Market portfolio of private equity and venture capital assets of Dr. Plattner's family office. Mr. Balkin is currently a partner at DiGame, a growth fund foced on Africa and the Middle East in which the key investor is Abu Dhabi Investment Counsel ("ADIC"). Mr. Balkin represents DiGame on the board of direct to consumer asset manager 10X Investments. Since 2004, Mr. Balkin has served on and chaired a range of venture capital and private equity fund investment committees as the representative of the limited partners or investors. These include Enablis, First National Bank Vumela Fund, Telkom Future Makers and Alithea IDF. Beten 2000 and 2007, Mr. Balkin was the founding partner of O2 Capital, a private equity fund manager for the Msele Nedventures Fund. The LPs in the fund included a range of development finance institutions such as Proparco (France), DEG (Germany) and IDC (South Africa) and the fund invested primarily in technology binesses in South Africa. Mr. Balkin obtained his BA in 1995 and his LLB in 1997 from University of Witwatersrand in Johannesburg.
Marc Balkin自2021年3月起担任我们的董事兼首席执行官。Balkin先生是Balkin and Co的创始人,这是一家咨询公司,自2015年以来一直为私人股本公司和家族理财室提供合并,收购和投资非洲的建议。惠普的客户包括SAP创始人兼现任董事长Hasso Plattner博士的家族办公室、Omidyar Network(eBay创始人Pierre Omidyar家族办公室的一部分)和兰德商业银行。在创立Balkin and Co之前,Balkin先生是Hasso PlattnerVentures Africa的管理合伙人,这是一家风险基金,其中Plattner博士是关键的有限合伙人。Balkin先生还负责管理Plattner博士家族办公室的私人股本和风险资本资产的新兴市场投资组合。Balkin先生目前是Digame的合伙人,这是一家专注于非洲和中东的成长型基金,其主要投资者是阿布扎比投资顾问公司(“;ADIC”;)。Balkin先生在Direct-to-Consumer Asset Manager10X Investments的董事会中代表Digame,自2004年以来,Balkin先生在一系列风险资本和私募股权基金投资委员会任职并担任主席,作为有限合伙人或投资者的代表。这些公司包括Enablis、第一国民银行Vumela基金、Telkom Future Makers和Alithea IDF。从2000年到2007年,Balkin先生是O2Capital的创始合伙人,这是一家Msele Nedventures Fund的私募股权基金经理。该基金的有限合伙人包括一系列发展融资机构,如Proparco(法国)、DEG(德国)和IDC(南非),该基金主要投资于南非的技术企业。Balkin先生于1995年获得学士学位,并于1997年在约翰内斯堡的威特沃特斯兰德大学获得法学学士学位。
Marc Balkin has served as a director of the Company since January 25, 2024. He served as the Chief Executive Officer and served as a member of the board of directors of NCAC from March 2021 until January 25, 2024. Mr. Balkin is a founder of Balkin and Co, an advisory firm that has advised private equity firms and family offices on mergers, acquisitions and investments in Africa since 2015. Clients have included HP Bet (part of the family office of Dr. Hasso Plattner, a founder and current Chairman of SAP), Omidyar Network (part of the family office of Pierre Omidyar, the founder of eBay) and Rand Merchant Bank. Prior to founding Balkin and Co, Mr. Balkin was the Managing Partner of Hasso Plattner Ventures Africa, a Venture Fund in which Dr. Plattner was the key limited partner. Mr. Balkin also held responsibility for managing the Emerging Market portfolio of private equity and venture capital assets of Dr. Plattner's family office. Mr. Balkin is currently a partner at DiGame, a growth fund foced on Africa and the Middle East in which the key investor is Abu Dhabi Investment Counsel ("ADIC"). Mr. Balkin represents DiGame on the board of direct to consumer asset manager 10X Investments. Since 2004, Mr. Balkin has served on and chaired a range of venture capital and private equity fund investment committees as the representative of the limited partners or investors. These include Enablis, First National Bank Vumela Fund, Telkom Future Makers and Alithea IDF. Beten 2000 and 2007, Mr. Balkin was the founding partner of O2 Capital, a private equity fund manager for the Msele Nedventures Fund. The LPs in the fund included a range of development finance institutions such as Proparco (France), DEG (Germany) and IDC (South Africa) and the fund invested primarily in technology binesses in South Africa. Mr. Balkin obtained his BA in 1995 and his LLB in 1997 from University of Witwatersrand in Johannesburg.
Christopher Bull

Christopher Bull自2024年1月25日起担任公司董事,自2022年12月起担任PGI战略顾问。Chris是一名合格的化学工程师、律师、专利律师和认证许可专业人员.在其三十年的职业生涯中,Bull先生一直是欧洲和北美一系列成功公司的投资者、董事、创始人和顾问,在制药、生物技术、食品科学、化学加工和提取技术领域拥有新技术。他自2024年4月起担任PsyLabs的顾问,PsyLabs是一家私营公司,专门生产用于研究、临床试验和药物开发的迷幻活性药物成分和提取物,是公司的关联公司,自2023年11月起担任PsyLabs的全资子公司Psyence UK Group Ltd.的董事会成员。Bull先生曾担任一家风险投资公司(Knife Capital)的董事长和董事。Bull先生还通过获得多项国际奖项获得认可,包括IAM Strategy 300、IAM Patent 1000、IAM Licensing 250;EuroMoney Expert Guides:世界领先的专利律师;Chambers and Partners的全球指南世界领先律师法律500强指南杰出律师,以表彰他在为高科技公司开发和执行风险资本投资、专利和知识产权战略方面的技能。


Christopher Bull has served as a director of the Company since January 25, 2024 and has served as a strategic advisor of PGI since December 2022. Chris is a qualified chemical engineer, attorney, patent attorney and Certified Licensing Professional. Over his thirty year career, Mr. Bull has been an investor, director, founder and advisor to a range of successful companies in Europe and North America with novel technologies in the fields of pharmaceuticals, biotechnology, food sciences, chemical processing, and extraction technologies. He has been a consultant of PsyLabs, a privately held company specializing in the production of psychedelic active pharmaceutical ingredients and extracts for research, clinical trials, and drug development and an affiliate of the Company, since April 2024 and a board member of Psyence UK Group Ltd., a wholly owned subsidiary of PsyLabs, since November 2023. Mr. Bull has served as a Chairman and director of a venture capital firm (Knife Capital).
Christopher Bull自2024年1月25日起担任公司董事,自2022年12月起担任PGI战略顾问。Chris是一名合格的化学工程师、律师、专利律师和认证许可专业人员.在其三十年的职业生涯中,Bull先生一直是欧洲和北美一系列成功公司的投资者、董事、创始人和顾问,在制药、生物技术、食品科学、化学加工和提取技术领域拥有新技术。他自2024年4月起担任PsyLabs的顾问,PsyLabs是一家私营公司,专门生产用于研究、临床试验和药物开发的迷幻活性药物成分和提取物,是公司的关联公司,自2023年11月起担任PsyLabs的全资子公司Psyence UK Group Ltd.的董事会成员。Bull先生曾担任一家风险投资公司(Knife Capital)的董事长和董事。Bull先生还通过获得多项国际奖项获得认可,包括IAM Strategy 300、IAM Patent 1000、IAM Licensing 250;EuroMoney Expert Guides:世界领先的专利律师;Chambers and Partners的全球指南世界领先律师法律500强指南杰出律师,以表彰他在为高科技公司开发和执行风险资本投资、专利和知识产权战略方面的技能。
Christopher Bull has served as a director of the Company since January 25, 2024 and has served as a strategic advisor of PGI since December 2022. Chris is a qualified chemical engineer, attorney, patent attorney and Certified Licensing Professional. Over his thirty year career, Mr. Bull has been an investor, director, founder and advisor to a range of successful companies in Europe and North America with novel technologies in the fields of pharmaceuticals, biotechnology, food sciences, chemical processing, and extraction technologies. He has been a consultant of PsyLabs, a privately held company specializing in the production of psychedelic active pharmaceutical ingredients and extracts for research, clinical trials, and drug development and an affiliate of the Company, since April 2024 and a board member of Psyence UK Group Ltd., a wholly owned subsidiary of PsyLabs, since November 2023. Mr. Bull has served as a Chairman and director of a venture capital firm (Knife Capital).
Jody Aufrichtig

Jody Aufrichtig自2024年1月25日起担任战略BINCE发展官兼董事会主席,自2020年5月21日起担任PGI董事。自2020年5月21日起,他在PGI担任相同职务。Aufrichtig先生是一位特许会计师和经验丰富的企业家,在新兴市场拥有丰富的经验。他自2024年4月起担任PsyLabs的顾问,PsyLabs是一家私人控股公司,专门生产用于研究、临床试验和药物开发的迷幻活性药物成分和提取物,是公司的关联公司,自2021年4月起担任PsyLabs的全资子公司Psyence South Africa(Pty)Ltd.的董事会成员.。Aufrichtig先生是MindHealth Biomed Corp的创始人,他建立了多个获奖的binesses,并在大麻、商业和住宅物业、私募股权、tism、休闲和其他行业创造了可观的股东价值。在创立MindHealth Biomed Corp之前,从2018年5月起,他担任Canopy Growth非洲(Canopy Growth Corporation(纽约证券交易所代码:CGC/TSX:ED)的全资子公司)的董事总经理,直到2020年4月他领导了非洲业务的管理层收购。Aufrichtig先生于2017年7月创立了Daddy Cann Lesotho(Pty)Limited,并获得了卫生部(莱索托)颁发的种植、制造、供应、持有、进口、出口和运输大麻的许可证。Daddy Cann Lesotho(Pty)Limited随后于2018年5月被Canopy Growth Corporation收购。2000年,Aufrichtig Co.先生创立了Indigo Properties,这是一家专注于商业和住宅物业、tism和休闲的biness。Aufrichtig先生拥有南非开普敦大学会计学学士学位和荣誉会计学学士学位,并在南非特许会计师协会注册。


Jody Aufrichtig has served as Strategic Biness Development Officer and Chairman of the Board since January 25, 2024, and a Director of PGI since May 21, 2020. He has served in the same roles at PGI since May 21, 2020. Mr. Aufrichtig is a chartered accountant and experienced entrepreneur with extensive experience in emerging markets. He has served as a consultant of PsyLabs, a privately held company specializing in the production of psychedelic active pharmaceutical ingredients and extracts for research, clinical trials, and drug development and an affiliate of the Company, since April 2024 and a board member of Psyence South Africa (Pty) Ltd., a wholly owned subsidiary of PsyLabs, since April 2021.. Mr. Aufrichtig is the founder of MindHealth Biomed Corp and has built multiple award winning binesses and created substantial shareholder value in cannabis, commercial and residential property, private equity, tism, leisure and other indtries. Prior to founding MindHealth Biomed Corp, he was the Managing Director of Canopy Growth Africa (a wholly owned subsidiary of Canopy Growth Corporation (NYSE: CGC / TSX: ED)) from May 2018 until he led a management buyout of the African operations in April 2020. Mr. Aufrichtig founded Daddy Cann Lesotho (Pty) Limited in July 2017 and was granted a license by the Ministry of Health (Lesotho) to cultivate, manufacture, supply, hold, import, export and transport cannabis. Daddy Cann Lesotho (Pty) Limited was subsequently acquired by Canopy Growth Corporation in May 2018. In 2000, Mr. Aufrichtig co founded Indigo Properties, a biness foced on commercial and residential property, tism and leisure. Mr. Aufrichtig holds a Bachelor of Accounting and a Bachelor of Accounting Hons from the University of Cape Town, South Africa and is registered with the South African Institute of Chartered Accountants.
Jody Aufrichtig自2024年1月25日起担任战略BINCE发展官兼董事会主席,自2020年5月21日起担任PGI董事。自2020年5月21日起,他在PGI担任相同职务。Aufrichtig先生是一位特许会计师和经验丰富的企业家,在新兴市场拥有丰富的经验。他自2024年4月起担任PsyLabs的顾问,PsyLabs是一家私人控股公司,专门生产用于研究、临床试验和药物开发的迷幻活性药物成分和提取物,是公司的关联公司,自2021年4月起担任PsyLabs的全资子公司Psyence South Africa(Pty)Ltd.的董事会成员.。Aufrichtig先生是MindHealth Biomed Corp的创始人,他建立了多个获奖的binesses,并在大麻、商业和住宅物业、私募股权、tism、休闲和其他行业创造了可观的股东价值。在创立MindHealth Biomed Corp之前,从2018年5月起,他担任Canopy Growth非洲(Canopy Growth Corporation(纽约证券交易所代码:CGC/TSX:ED)的全资子公司)的董事总经理,直到2020年4月他领导了非洲业务的管理层收购。Aufrichtig先生于2017年7月创立了Daddy Cann Lesotho(Pty)Limited,并获得了卫生部(莱索托)颁发的种植、制造、供应、持有、进口、出口和运输大麻的许可证。Daddy Cann Lesotho(Pty)Limited随后于2018年5月被Canopy Growth Corporation收购。2000年,Aufrichtig Co.先生创立了Indigo Properties,这是一家专注于商业和住宅物业、tism和休闲的biness。Aufrichtig先生拥有南非开普敦大学会计学学士学位和荣誉会计学学士学位,并在南非特许会计师协会注册。
Jody Aufrichtig has served as Strategic Biness Development Officer and Chairman of the Board since January 25, 2024, and a Director of PGI since May 21, 2020. He has served in the same roles at PGI since May 21, 2020. Mr. Aufrichtig is a chartered accountant and experienced entrepreneur with extensive experience in emerging markets. He has served as a consultant of PsyLabs, a privately held company specializing in the production of psychedelic active pharmaceutical ingredients and extracts for research, clinical trials, and drug development and an affiliate of the Company, since April 2024 and a board member of Psyence South Africa (Pty) Ltd., a wholly owned subsidiary of PsyLabs, since April 2021.. Mr. Aufrichtig is the founder of MindHealth Biomed Corp and has built multiple award winning binesses and created substantial shareholder value in cannabis, commercial and residential property, private equity, tism, leisure and other indtries. Prior to founding MindHealth Biomed Corp, he was the Managing Director of Canopy Growth Africa (a wholly owned subsidiary of Canopy Growth Corporation (NYSE: CGC / TSX: ED)) from May 2018 until he led a management buyout of the African operations in April 2020. Mr. Aufrichtig founded Daddy Cann Lesotho (Pty) Limited in July 2017 and was granted a license by the Ministry of Health (Lesotho) to cultivate, manufacture, supply, hold, import, export and transport cannabis. Daddy Cann Lesotho (Pty) Limited was subsequently acquired by Canopy Growth Corporation in May 2018. In 2000, Mr. Aufrichtig co founded Indigo Properties, a biness foced on commercial and residential property, tism and leisure. Mr. Aufrichtig holds a Bachelor of Accounting and a Bachelor of Accounting Hons from the University of Cape Town, South Africa and is registered with the South African Institute of Chartered Accountants.
Seth Feuerstein

Seth Feuerstein自2024年1月25日起担任公司董事。Feuerstein博士在多个医学领域拥有专长,包括自杀预防、技术和自杀、远程医疗、社交媒体和心理健康、数字医学、自杀、Digital Health、数字疗法、医疗保健创新、新兴医疗技术、法医精神病学、技术转让、技术投资、知识产权以及技术、法律和医学的交叉领域。他是耶鲁大学生物医学和介入技术中心的创始董事会成员,也是Digital Health、创新和卓越中心的执行主任。自2004年以来,他一直在耶鲁大学医学院精神病学系任教,并且是该医学院医疗保健创新的教师顾问。他在医疗保健的多个领域工作,包括健康保险、医疗保健初创公司、医疗保健投资、临床护理提供创新和早期新兴医疗技术。他是Oui Therapeutics,Inc.自2019年以来的创始人兼首席执行官,该公司正在开发一种用于减少自杀未遂的处方数字疗法。自2019年6月以来,Feuerstein博士已被任命为国防部高级顾问/高度合格顾问(HQE),就行为健康创新提供建议。2014年至2018年8月,他担任Magellan Healthcare的首席医疗和创新官。他还在多家生物技术和医疗保健公司共同创立和/或担任领导职务。Feuerstein博士在康奈尔大学获得理学学士学位,在纽约大学法学院获得法学博士学位,在纽约大学医学院获得医学博士学位。


Seth Feuerstein has served as a director of the Company since January 25, 2024. Dr. Feuerstein has expertise across multiple areas of medicine including Suicide Prevention, Technology and Suicide, Telehealth, Social Media and Mental Health, Digital Medicine, Suicide, Digital Health, Digital Therapeutics, Healthcare Innovation, Emerging Medical Technologies, forensic psychiatry, technology transfer, technology investment, intellectual property and the intersection of technology, law and medicine. He is a founding board member of the Center for Biomedical and Interventional Technology at Yale and Executive Director of the Center for Digital Health, Innovation and Excellence. He has been teaching at the Yale School of Medicine, Department of Psychiatry, since 2004 and is the faculty advisor for Innovation in Healthcare at the medical school. He works across multiple sectors in healthcare including health insurance, healthcare startups, healthcare investing, clinical care delivery innovation and early stage emerging medical technologies. He is the founder and CEO of Oui Therapeutics, Inc. Since 2019, which is developing a prescription digital therapeutic for suicide attempt reduction. Dr. Feuerstein has been appointed senior advisor/Highly Qualified Advisor (HQE) for the Department of Defense, advising on behavioral health innovation, since June 2019. From 2014 to Augt 2018, he was the chief medical and innovation officer at Magellan Healthcare. He has also co founded and/or held leadership roles in a number of biotechnology and healthcare companies. Dr. Feuerstein received his Bachelor of Science from Cornell University, a J.D. from New York University School of Law, and an M.D. from New York University School of Medicine.
Seth Feuerstein自2024年1月25日起担任公司董事。Feuerstein博士在多个医学领域拥有专长,包括自杀预防、技术和自杀、远程医疗、社交媒体和心理健康、数字医学、自杀、Digital Health、数字疗法、医疗保健创新、新兴医疗技术、法医精神病学、技术转让、技术投资、知识产权以及技术、法律和医学的交叉领域。他是耶鲁大学生物医学和介入技术中心的创始董事会成员,也是Digital Health、创新和卓越中心的执行主任。自2004年以来,他一直在耶鲁大学医学院精神病学系任教,并且是该医学院医疗保健创新的教师顾问。他在医疗保健的多个领域工作,包括健康保险、医疗保健初创公司、医疗保健投资、临床护理提供创新和早期新兴医疗技术。他是Oui Therapeutics,Inc.自2019年以来的创始人兼首席执行官,该公司正在开发一种用于减少自杀未遂的处方数字疗法。自2019年6月以来,Feuerstein博士已被任命为国防部高级顾问/高度合格顾问(HQE),就行为健康创新提供建议。2014年至2018年8月,他担任Magellan Healthcare的首席医疗和创新官。他还在多家生物技术和医疗保健公司共同创立和/或担任领导职务。Feuerstein博士在康奈尔大学获得理学学士学位,在纽约大学法学院获得法学博士学位,在纽约大学医学院获得医学博士学位。
Seth Feuerstein has served as a director of the Company since January 25, 2024. Dr. Feuerstein has expertise across multiple areas of medicine including Suicide Prevention, Technology and Suicide, Telehealth, Social Media and Mental Health, Digital Medicine, Suicide, Digital Health, Digital Therapeutics, Healthcare Innovation, Emerging Medical Technologies, forensic psychiatry, technology transfer, technology investment, intellectual property and the intersection of technology, law and medicine. He is a founding board member of the Center for Biomedical and Interventional Technology at Yale and Executive Director of the Center for Digital Health, Innovation and Excellence. He has been teaching at the Yale School of Medicine, Department of Psychiatry, since 2004 and is the faculty advisor for Innovation in Healthcare at the medical school. He works across multiple sectors in healthcare including health insurance, healthcare startups, healthcare investing, clinical care delivery innovation and early stage emerging medical technologies. He is the founder and CEO of Oui Therapeutics, Inc. Since 2019, which is developing a prescription digital therapeutic for suicide attempt reduction. Dr. Feuerstein has been appointed senior advisor/Highly Qualified Advisor (HQE) for the Department of Defense, advising on behavioral health innovation, since June 2019. From 2014 to Augt 2018, he was the chief medical and innovation officer at Magellan Healthcare. He has also co founded and/or held leadership roles in a number of biotechnology and healthcare companies. Dr. Feuerstein received his Bachelor of Science from Cornell University, a J.D. from New York University School of Law, and an M.D. from New York University School of Medicine.

高管简历

中英对照 |  中文 |  英文
Neil Maresky

Neil Maresky自2024年1月25日起担任公司首席执行官,并于2023年6月29日至2025年9月29日担任董事。Maresky博士还从2021年7月1日起担任PGI的首席执行官和董事,直到2024年3月辞职。Maresky博士带来了超过25年的企业领导和生物制药专业知识,目前负责监督Psyence的战略和运营。从2010年到2021年,Maresky博士在阿斯利康加拿大公司担任了十多年的科学事务副总裁。Maresky博士是南非受过训练的医生。在加拿大,他曾在“Big Pharma”担任多个行政领导职务,包括在拜耳制药(1998年至2002年)领导研发和推动科学战略,以及在2008年担任临时总裁兼总经理的惠氏制药(2002年至2008年)。Maresky博士是一名南非受过培训的医生,在那里他接受了急诊室医学和心脏病学方面的培训,并以家庭医生的身份执业。20世纪90年代中期,马雷斯基博士移居加拿大,开始了他在制药工业的职业生涯。在其职业生涯的CSE期间,Maresky博士对加拿大各地数百万患者的健康产生了积极影响。凭借丰富的经验以及与加拿大各地学术机构、卫生当局和决策机构的关系,Maresky博士为许多创新医学疗法和技术做出了贡献,包括50多个新药和新适应症的批准。Maresky博士最近的成就之一是加拿大卫生部批准了阿斯利康新冠19疫苗。Maresky博士拥有威特沃特斯兰德大学医学硕士、学士学位(1987年)。


Neil Maresky has served as he Company's Chief Executive Officer since January 25, 2024 and Director from June 29, 2023 to September 29, 2025. Dr. Maresky has also served as PGI's chief executive officer and director from July 1, 2021 until his resignation in March 2024. Dr. Maresky currently oversees the strategy and operations of Psyence. From 2010 to 2021, Dr. Maresky, spent more than a decade at AstraZeneca Canada as Vice President of Scientific Affairs. Dr. Maresky is a South African trained doctor. In Canada, he has held vario executive leadership positions in "Big Pharma", including leading research and development and driving scientific strategy at Bayer Pharmaceuticals (1998 2002) as ll as Wyeth Pharmaceuticals (2002 2008), where he was interim President and general manager in 2008. Dr. Maresky is a South African trained doctor where he was trained in emergency room medicine and cardiology, and practiced as a family physician. In the mid 1990s, Dr. Maresky emigrated to Canada and began his career in the pharmaceutical indtry. During the cse of his career, Dr. Maresky has positively impacted the health of millions of patients across Canada. With extensive experience and relationships with academic institutions, health authorities and decision making bodies across Canada, Dr. Maresky has contributed to many innovative medical therapies and technologies, including over 50 approvals of new medicines and new indications. One of Dr. Maresky's most recent achievements was the approval of the AstraZeneca Covid 19 vaccine by Health Canada. Dr. Maresky holds a Medical Degree M.B.,B.Ch. from the University of Witwatersrand (1987).
Neil Maresky自2024年1月25日起担任公司首席执行官,并于2023年6月29日至2025年9月29日担任董事。Maresky博士还从2021年7月1日起担任PGI的首席执行官和董事,直到2024年3月辞职。Maresky博士带来了超过25年的企业领导和生物制药专业知识,目前负责监督Psyence的战略和运营。从2010年到2021年,Maresky博士在阿斯利康加拿大公司担任了十多年的科学事务副总裁。Maresky博士是南非受过训练的医生。在加拿大,他曾在“Big Pharma”担任多个行政领导职务,包括在拜耳制药(1998年至2002年)领导研发和推动科学战略,以及在2008年担任临时总裁兼总经理的惠氏制药(2002年至2008年)。Maresky博士是一名南非受过培训的医生,在那里他接受了急诊室医学和心脏病学方面的培训,并以家庭医生的身份执业。20世纪90年代中期,马雷斯基博士移居加拿大,开始了他在制药工业的职业生涯。在其职业生涯的CSE期间,Maresky博士对加拿大各地数百万患者的健康产生了积极影响。凭借丰富的经验以及与加拿大各地学术机构、卫生当局和决策机构的关系,Maresky博士为许多创新医学疗法和技术做出了贡献,包括50多个新药和新适应症的批准。Maresky博士最近的成就之一是加拿大卫生部批准了阿斯利康新冠19疫苗。Maresky博士拥有威特沃特斯兰德大学医学硕士、学士学位(1987年)。
Neil Maresky has served as he Company's Chief Executive Officer since January 25, 2024 and Director from June 29, 2023 to September 29, 2025. Dr. Maresky has also served as PGI's chief executive officer and director from July 1, 2021 until his resignation in March 2024. Dr. Maresky currently oversees the strategy and operations of Psyence. From 2010 to 2021, Dr. Maresky, spent more than a decade at AstraZeneca Canada as Vice President of Scientific Affairs. Dr. Maresky is a South African trained doctor. In Canada, he has held vario executive leadership positions in "Big Pharma", including leading research and development and driving scientific strategy at Bayer Pharmaceuticals (1998 2002) as ll as Wyeth Pharmaceuticals (2002 2008), where he was interim President and general manager in 2008. Dr. Maresky is a South African trained doctor where he was trained in emergency room medicine and cardiology, and practiced as a family physician. In the mid 1990s, Dr. Maresky emigrated to Canada and began his career in the pharmaceutical indtry. During the cse of his career, Dr. Maresky has positively impacted the health of millions of patients across Canada. With extensive experience and relationships with academic institutions, health authorities and decision making bodies across Canada, Dr. Maresky has contributed to many innovative medical therapies and technologies, including over 50 approvals of new medicines and new indications. One of Dr. Maresky's most recent achievements was the approval of the AstraZeneca Covid 19 vaccine by Health Canada. Dr. Maresky holds a Medical Degree M.B.,B.Ch. from the University of Witwatersrand (1987).
Warwick Corden Lloyd

华威科登劳埃德自2024年1月25日起担任公司首席财务官。Corden Lloyd先生还自2020年5月21日起担任PGI的首席财务官,至2024年1月辞职。Corden Lloyd先生是一名特许会计师和注册项目经理。他在英国和南非的公共会计、咨询和上市金融服务公司拥有超过19年的工作经验。Corden Lloyd先生在国际和新兴市场拥有上市公司财务和监管报告经验。他自2024年4月起担任PsyLabs的顾问,PsyLabs是一家私人控股公司,专门生产用于研究、临床试验和药物开发的迷幻活性药物成分和提取物,是公司的关联公司,自2022年3月起担任PsyLabs的全资子公司Psyence UK Group Ltd.的董事会成员。从2020年5月至2021年1月,Corden Lloyd先生曾担任MindHealth Biomed Corp(PGI之前的前身公司)的企业融资顾问和首席财务官。Corden Lloyd先生于2019年5月至2020年5月期间担任Canopy Growth非洲公司(Canopy Growth Corporation(纽约证券交易所代码:CGC/TSX:ED)的全资子公司)的运营和财务副总裁。在Canopy Growth期间,他负责监督财务、法律、供应链、人力资源、质量保证和监管、项目管理和国家经理部门。在此之前,他于2015年2月至2019年5月担任南非最大的CTomer零售银行Capitec Bank的财务会计主管,负责管理该银行的财务和监管报告、预算编制和财务会计。在任职于凯德银行之前,他曾任职于南非普华永道国际有限公司、英国以及英国纽约梅隆银行公司。Corden Lloyd先生于2002年获得南非斯泰伦博斯大学会计学学士学位,2003年获得南非纳塔尔大学会计学荣誉学士学位,并于2006年在南非特许会计师协会注册。他还在英格兰和威尔士的特许会计师协会注册。


Warwick Corden Lloyd has served as the Chief Financial Officer of the Company since January 25, 2024. Mr. Corden Lloyd has also served as Chief Financial Officer of PGI from May 21, 2020 until his resignation in January 2024. Mr. Corden Lloyd is a Chartered Accountant and Certified Project Manager. He has over 19 years of experience working in public accounting, consulting and listed financial services companies in the UK, and South Africa. Mr. Corden Lloyd has listed company financial and regulatory reporting experience in international and emerging markets. He has been a consultant of PsyLabs, a privately held company specializing in the production of psychedelic active pharmaceutical ingredients and extracts for research, clinical trials, and drug development and an affiliate of the Company, since April 2024 and a board member of Psyence UK Group Ltd., a wholly owned subsidiary of PsyLabs, since March 2022. From May 2020 to January 2021, Mr. Corden Lloyd was the Corporate Finance Advisor and Chief Financial Officer of MindHealth Biomed Corp, the predecessor company prior to PGI. Mr. Corden Lloyd was previoly the Vice President of Operations and Finance at Canopy Growth Africa, a wholly owned subsidiary of Canopy Growth Corporation (NYSE: CGC / TSX: ED) from May 2019 to May 2020. Whilst at Canopy Growth, he oversaw the Finance, Legal, Supply Chain, Human Resces, Quality Assurance and Regulatory, Project Management and Country Manager divisions. Prior to that he was Head of Financial Accounting at Capitec Bank, South Africa's largest ctomer retail bank, from February 2015 to May 2019 where he was responsible for managing the financial and regulatory reporting, budgeting and financial accounting for the bank. Before working at Capitec Bank, he worked for PricewaterhoeCoopers International Limited in South Africa, and the UK and for The Bank of New York Mellon Corporation in the UK. Mr. Corden Lloyd received a Bachelor of Accounting from the University of Stellenbosch, South Africa in 2002, a Bachelor of Accounting Hons from the University of Natal, South Africa in 2003 and registered with the South African Institute of Chartered Accountants in 2006. He is also registered with The Institute of Chartered Accountants in England and Wales.
华威科登劳埃德自2024年1月25日起担任公司首席财务官。Corden Lloyd先生还自2020年5月21日起担任PGI的首席财务官,至2024年1月辞职。Corden Lloyd先生是一名特许会计师和注册项目经理。他在英国和南非的公共会计、咨询和上市金融服务公司拥有超过19年的工作经验。Corden Lloyd先生在国际和新兴市场拥有上市公司财务和监管报告经验。他自2024年4月起担任PsyLabs的顾问,PsyLabs是一家私人控股公司,专门生产用于研究、临床试验和药物开发的迷幻活性药物成分和提取物,是公司的关联公司,自2022年3月起担任PsyLabs的全资子公司Psyence UK Group Ltd.的董事会成员。从2020年5月至2021年1月,Corden Lloyd先生曾担任MindHealth Biomed Corp(PGI之前的前身公司)的企业融资顾问和首席财务官。Corden Lloyd先生于2019年5月至2020年5月期间担任Canopy Growth非洲公司(Canopy Growth Corporation(纽约证券交易所代码:CGC/TSX:ED)的全资子公司)的运营和财务副总裁。在Canopy Growth期间,他负责监督财务、法律、供应链、人力资源、质量保证和监管、项目管理和国家经理部门。在此之前,他于2015年2月至2019年5月担任南非最大的CTomer零售银行Capitec Bank的财务会计主管,负责管理该银行的财务和监管报告、预算编制和财务会计。在任职于凯德银行之前,他曾任职于南非普华永道国际有限公司、英国以及英国纽约梅隆银行公司。Corden Lloyd先生于2002年获得南非斯泰伦博斯大学会计学学士学位,2003年获得南非纳塔尔大学会计学荣誉学士学位,并于2006年在南非特许会计师协会注册。他还在英格兰和威尔士的特许会计师协会注册。
Warwick Corden Lloyd has served as the Chief Financial Officer of the Company since January 25, 2024. Mr. Corden Lloyd has also served as Chief Financial Officer of PGI from May 21, 2020 until his resignation in January 2024. Mr. Corden Lloyd is a Chartered Accountant and Certified Project Manager. He has over 19 years of experience working in public accounting, consulting and listed financial services companies in the UK, and South Africa. Mr. Corden Lloyd has listed company financial and regulatory reporting experience in international and emerging markets. He has been a consultant of PsyLabs, a privately held company specializing in the production of psychedelic active pharmaceutical ingredients and extracts for research, clinical trials, and drug development and an affiliate of the Company, since April 2024 and a board member of Psyence UK Group Ltd., a wholly owned subsidiary of PsyLabs, since March 2022. From May 2020 to January 2021, Mr. Corden Lloyd was the Corporate Finance Advisor and Chief Financial Officer of MindHealth Biomed Corp, the predecessor company prior to PGI. Mr. Corden Lloyd was previoly the Vice President of Operations and Finance at Canopy Growth Africa, a wholly owned subsidiary of Canopy Growth Corporation (NYSE: CGC / TSX: ED) from May 2019 to May 2020. Whilst at Canopy Growth, he oversaw the Finance, Legal, Supply Chain, Human Resces, Quality Assurance and Regulatory, Project Management and Country Manager divisions. Prior to that he was Head of Financial Accounting at Capitec Bank, South Africa's largest ctomer retail bank, from February 2015 to May 2019 where he was responsible for managing the financial and regulatory reporting, budgeting and financial accounting for the bank. Before working at Capitec Bank, he worked for PricewaterhoeCoopers International Limited in South Africa, and the UK and for The Bank of New York Mellon Corporation in the UK. Mr. Corden Lloyd received a Bachelor of Accounting from the University of Stellenbosch, South Africa in 2002, a Bachelor of Accounting Hons from the University of Natal, South Africa in 2003 and registered with the South African Institute of Chartered Accountants in 2006. He is also registered with The Institute of Chartered Accountants in England and Wales.
Jody Aufrichtig

Jody Aufrichtig自2024年1月25日起担任战略BINCE发展官兼董事会主席,自2020年5月21日起担任PGI董事。自2020年5月21日起,他在PGI担任相同职务。Aufrichtig先生是一位特许会计师和经验丰富的企业家,在新兴市场拥有丰富的经验。他自2024年4月起担任PsyLabs的顾问,PsyLabs是一家私人控股公司,专门生产用于研究、临床试验和药物开发的迷幻活性药物成分和提取物,是公司的关联公司,自2021年4月起担任PsyLabs的全资子公司Psyence South Africa(Pty)Ltd.的董事会成员.。Aufrichtig先生是MindHealth Biomed Corp的创始人,他建立了多个获奖的binesses,并在大麻、商业和住宅物业、私募股权、tism、休闲和其他行业创造了可观的股东价值。在创立MindHealth Biomed Corp之前,从2018年5月起,他担任Canopy Growth非洲(Canopy Growth Corporation(纽约证券交易所代码:CGC/TSX:ED)的全资子公司)的董事总经理,直到2020年4月他领导了非洲业务的管理层收购。Aufrichtig先生于2017年7月创立了Daddy Cann Lesotho(Pty)Limited,并获得了卫生部(莱索托)颁发的种植、制造、供应、持有、进口、出口和运输大麻的许可证。Daddy Cann Lesotho(Pty)Limited随后于2018年5月被Canopy Growth Corporation收购。2000年,Aufrichtig Co.先生创立了Indigo Properties,这是一家专注于商业和住宅物业、tism和休闲的biness。Aufrichtig先生拥有南非开普敦大学会计学学士学位和荣誉会计学学士学位,并在南非特许会计师协会注册。


Jody Aufrichtig has served as Strategic Biness Development Officer and Chairman of the Board since January 25, 2024, and a Director of PGI since May 21, 2020. He has served in the same roles at PGI since May 21, 2020. Mr. Aufrichtig is a chartered accountant and experienced entrepreneur with extensive experience in emerging markets. He has served as a consultant of PsyLabs, a privately held company specializing in the production of psychedelic active pharmaceutical ingredients and extracts for research, clinical trials, and drug development and an affiliate of the Company, since April 2024 and a board member of Psyence South Africa (Pty) Ltd., a wholly owned subsidiary of PsyLabs, since April 2021.. Mr. Aufrichtig is the founder of MindHealth Biomed Corp and has built multiple award winning binesses and created substantial shareholder value in cannabis, commercial and residential property, private equity, tism, leisure and other indtries. Prior to founding MindHealth Biomed Corp, he was the Managing Director of Canopy Growth Africa (a wholly owned subsidiary of Canopy Growth Corporation (NYSE: CGC / TSX: ED)) from May 2018 until he led a management buyout of the African operations in April 2020. Mr. Aufrichtig founded Daddy Cann Lesotho (Pty) Limited in July 2017 and was granted a license by the Ministry of Health (Lesotho) to cultivate, manufacture, supply, hold, import, export and transport cannabis. Daddy Cann Lesotho (Pty) Limited was subsequently acquired by Canopy Growth Corporation in May 2018. In 2000, Mr. Aufrichtig co founded Indigo Properties, a biness foced on commercial and residential property, tism and leisure. Mr. Aufrichtig holds a Bachelor of Accounting and a Bachelor of Accounting Hons from the University of Cape Town, South Africa and is registered with the South African Institute of Chartered Accountants.
Jody Aufrichtig自2024年1月25日起担任战略BINCE发展官兼董事会主席,自2020年5月21日起担任PGI董事。自2020年5月21日起,他在PGI担任相同职务。Aufrichtig先生是一位特许会计师和经验丰富的企业家,在新兴市场拥有丰富的经验。他自2024年4月起担任PsyLabs的顾问,PsyLabs是一家私人控股公司,专门生产用于研究、临床试验和药物开发的迷幻活性药物成分和提取物,是公司的关联公司,自2021年4月起担任PsyLabs的全资子公司Psyence South Africa(Pty)Ltd.的董事会成员.。Aufrichtig先生是MindHealth Biomed Corp的创始人,他建立了多个获奖的binesses,并在大麻、商业和住宅物业、私募股权、tism、休闲和其他行业创造了可观的股东价值。在创立MindHealth Biomed Corp之前,从2018年5月起,他担任Canopy Growth非洲(Canopy Growth Corporation(纽约证券交易所代码:CGC/TSX:ED)的全资子公司)的董事总经理,直到2020年4月他领导了非洲业务的管理层收购。Aufrichtig先生于2017年7月创立了Daddy Cann Lesotho(Pty)Limited,并获得了卫生部(莱索托)颁发的种植、制造、供应、持有、进口、出口和运输大麻的许可证。Daddy Cann Lesotho(Pty)Limited随后于2018年5月被Canopy Growth Corporation收购。2000年,Aufrichtig Co.先生创立了Indigo Properties,这是一家专注于商业和住宅物业、tism和休闲的biness。Aufrichtig先生拥有南非开普敦大学会计学学士学位和荣誉会计学学士学位,并在南非特许会计师协会注册。
Jody Aufrichtig has served as Strategic Biness Development Officer and Chairman of the Board since January 25, 2024, and a Director of PGI since May 21, 2020. He has served in the same roles at PGI since May 21, 2020. Mr. Aufrichtig is a chartered accountant and experienced entrepreneur with extensive experience in emerging markets. He has served as a consultant of PsyLabs, a privately held company specializing in the production of psychedelic active pharmaceutical ingredients and extracts for research, clinical trials, and drug development and an affiliate of the Company, since April 2024 and a board member of Psyence South Africa (Pty) Ltd., a wholly owned subsidiary of PsyLabs, since April 2021.. Mr. Aufrichtig is the founder of MindHealth Biomed Corp and has built multiple award winning binesses and created substantial shareholder value in cannabis, commercial and residential property, private equity, tism, leisure and other indtries. Prior to founding MindHealth Biomed Corp, he was the Managing Director of Canopy Growth Africa (a wholly owned subsidiary of Canopy Growth Corporation (NYSE: CGC / TSX: ED)) from May 2018 until he led a management buyout of the African operations in April 2020. Mr. Aufrichtig founded Daddy Cann Lesotho (Pty) Limited in July 2017 and was granted a license by the Ministry of Health (Lesotho) to cultivate, manufacture, supply, hold, import, export and transport cannabis. Daddy Cann Lesotho (Pty) Limited was subsequently acquired by Canopy Growth Corporation in May 2018. In 2000, Mr. Aufrichtig co founded Indigo Properties, a biness foced on commercial and residential property, tism and leisure. Mr. Aufrichtig holds a Bachelor of Accounting and a Bachelor of Accounting Hons from the University of Cape Town, South Africa and is registered with the South African Institute of Chartered Accountants.